Department of Health and Social Care on X: "Data from @UKHSA shows that a #COVID19 booster vaccine provides 88% protection against hospital admission from the #OmicronVariant. The booster jab is the best
![Second bivalent COVID-19 booster vaccine from Moderna (Spikevax) authorised by UK medicines regulator - GOV.UK Second bivalent COVID-19 booster vaccine from Moderna (Spikevax) authorised by UK medicines regulator - GOV.UK](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/image_data/file/176260/s960_Covid_vaccines_Gov_UK.jpg)
Second bivalent COVID-19 booster vaccine from Moderna (Spikevax) authorised by UK medicines regulator - GOV.UK
![COVID vaccinations: questions and answers about the rollout in North Yorkshire - NHS North Yorkshire CCG COVID vaccinations: questions and answers about the rollout in North Yorkshire - NHS North Yorkshire CCG](https://northyorkshireccg.nhs.uk/wp-content/uploads/2022/01/Covid-Vaccine-Eligibility-v4-scaled.jpg)
COVID vaccinations: questions and answers about the rollout in North Yorkshire - NHS North Yorkshire CCG
![COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study - The Lancet Infectious Diseases COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/372ade5e-5f14-48a9-b960-4b5767839337/gr1_lrg.jpg)
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study - The Lancet Infectious Diseases
![Safety and immunogenicity of seven COVID-19 vaccines as a third dose ( booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial - Safety and immunogenicity of seven COVID-19 vaccines as a third dose ( booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -](https://www.thelancet.com/cms/attachment/966d70c5-8395-4ea2-9a35-94dc18f2f550/gr1.gif)